- Home
- NYC vs CPHI Comparison
NYC vs CPHI Comparison
Compare NYC & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NYC | CPHI |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5M | 26.3M |
| IPO Year | 2014 | 2008 |
Fundamental Metrics
Financial Performance| Metric | NYC | CPHI |
|---|---|---|
| Price | $9.99 | $0.71 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.0K | ★ 324.1K |
| Earning Date | 04-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $4,144,268.00 |
| Revenue This Year | $56.73 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.03 | $0.38 |
| 52 Week High | $16.30 | $2.60 |
Technical Indicators
Market Signals| Indicator | NYC | CPHI |
|---|---|---|
| Relative Strength Index (RSI) | 66.41 | 50.82 |
| Support Level | $7.76 | $0.52 |
| Resistance Level | $11.99 | $1.87 |
| Average True Range (ATR) | 1.14 | 0.20 |
| MACD | 0.26 | 0.02 |
| Stochastic Oscillator | 46.84 | 32.08 |
Price Performance
Historical ComparisonAbout NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About CPHI China Pharma Holdings Inc.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.